QUANTITATIVE DETERMINATION OF CRIZOTINIB IN HUMAN PLASMA WITH HIGHPERFORMANCE LIQUID CHROMATOGRAPHY AND ULTRAVIOLET DETECTION
DOI:
https://doi.org/10.22159/ajpcr.2019.v12i2.29272Keywords:
Tyrosine kinase inhibitor, Anaplastic lymphoma kinase, Crizotinib, Liquid-extraction, PharmacokineticsAbstract
Objective: A rapid, sensitive, selective, and reproducible reversed-phase high-performance liquid chromatographic method has been developed and validated for the determination of crizotinib (CRZ), a tyrosine kinase inhibitor for targeted therapy of anaplastic lymphoma kinase-positive non-small-cell lung cancer.
Methods: The chromatographic separation was carried out in an isocratic mode on an YMC ODS C18 column with a mobile phase consisting of methanol and water containing 0.1% orthophosphoric acid in the ratio of 50:50 v/v at a flow rate of 0.6 ml/min. The run time was maintained for 10 min and detection was monitored at 267 nm. The method involved reproducible liquid-liquid extraction of drug from human plasma using diethyl ether as extracting solvent.
Results: CRZ and internal standard retention times were 6.86 and 7.94 min, respectively. Calibration curves were linear over a concentration range of 20.41–2041.14 ng/ml with correlation coefficient 0.9994. The lower limit of quantification for CRZ in plasma was 20 ng/ml. No endogenous substances were found to interfere with the peaks of drug and internal standard. The intra- and inter-day precision was <9.0% and the accuracy ranged from 97% to 112% over the linear range. All stability studies showed that CRZ in plasma sample was stable.
Conclusion: This method was found to be simple, selective, precise, accurate, and cost-effective. Hence, the method can be successfully applied to analyze the CRZ concentration in plasma samples for pharmacokinetic and bioequivalence studies.
Downloads
References
Iams WT, Lovly CM. Anaplastic lymphoma kinase as a therapeutic target in non-small cell lung cancer. Cancer J 2015;21:378-82.
Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Eng J Med 2014;371:2167-77.
Shaw AT, Kim DW, Nakagawa K, Seto T, Crinó L, Ahn MJ, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013;368:2385-94.
Li C, Alvey C, Bello A, Wilner KD, Tan W. Pharmacokinetics of crizotinib (PF-02341066) in patients with advanced non-small cell lung cancer (NSCLC) and other solid tumors. J Clin Oncol 2011;29:13065.
Herbrink M, de Vries N, Rosing H, Huitema AD, Nuijen B, Schellens JH, et al. Development and validation of a liquid chromatography-tandem mass spectrometry analytical method for the therapeutic drug monitoring of eight novel anticancer drugs. Biomed Chromatogr 2018;32:1-9.
Sparidans RW, Tang SC, Nguyen LN, Schinkel AH, Schellens JH, Beijnen JH. Liquid chromatography-tandem mass spectrometric assay for the ALK inhibitor crizotinib in mouse plasma. J Chromatogr B 2012;905:150-4.
Wani T, Lqbal M, Darwish I, Khalil N, Zargar S. Development and validation of sensitive UPLC-MS/MS based method for the estimation of crizotinib in human plasma. Dig J Nanometer Biostruct 2014;9:693 704.
Huang X, Cai J, Wang X. LC-MS determination of crizotinib in rat plasma and it application to a pharmacokinetic study. Lat Am J Pharm 2014;33:1188-92.
Michael SR, David CT, Alberto B, Clinton FS. Determination of crizotinib in human and mouse plasma by liquid chromatography electrospray ionization-tandem mass spectrometry (LC-ESI-MS/MS). J Chromatogr B 2014;960:151-7.
Khalil NY, Wani TA, Darwish IA, Al-Majed RA. Highly sensitive HPLC method with non-extractive sample preparation and fluorescence detection for determination of crizotinib in human plasma. Lat Am J Pharm 2014;33:1019-26.
Hany WD, Ahmed HB, Ibrahim AD. Enhanced spectrofluorimetric determination of the multitargeted tyrosinase kinase inhibitor crizotinib in human plasma via micelle-mediated approach. Trop J Pharm Res 2016;15:2209-17.
Vijayakumar B, Suman E, Sreekanth G. Estimation of crizotinib in capsule dosage form by RP-HPLC. IOSR J Pharm Biol Sci 2016;11:93 103.
Guidance for Industry. Bioanalytical Method Validation. Rockville, MD: U.S. Department of Health and Human Services, Food and Drug Administration Center for Drug Evaluation and Research; 2001.
Singh Y, Hidau MK, Misra A, Kushwaha HN, Tiwari A, Sharma AK, et al. UFLC method development and validation of a novel triethylamine containing thiophene S006-830-an antitubercular molecule and its application to pharmacokinetic and bioavailability studies in SD rats. Drug Test Anal 2015;7:721-6.
Togami K, Fukuda K, Yamaguchi K, Chono S, Tada H. Facile and sensitive HPLC-UV method for determination of nintedanib in rat plasma. Int J Pharm Pharm Sci 2018;10:133-7.
Kraak JC, Crombeen JP, Brelmer DD, Spewer P. Sample Pretreatment in Bio-Analysis. Amsterdam: Elsevier; 1987. p. 123-35.
Madhavi S, Rani AP. Bioanalytical method development and valiation for the determination of sofosbuvir from human plasma. Int J Pharm Pharm Sci 2017;9:35-41.
Jinesh BN, Bannimath G. Simultaneous estimation of clopidogrel and atorvastatin in human plasma using bio-analytical RP-Ultra fast liquid chromatographic method. Int J Curr Pharm Res 2015;7:30-5.
Published
How to Cite
Issue
Section
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
